CDIO (Cardio Diagnostics) Rentabilitas dodolan miturut bathi reged

Simbol resmi perusahaan Cardio Diagnostics (CDIO)

Cardio Diagnostics is implementing AI-driven blood screenings for the early detection of myocardial infarctions, ensuring steady demand for consumables. The EpiCheck platform utilizes robotics for the precision analysis of ischemia DNA markers. The gross margin reflects current business efficiency, where a metric value of -2231.90 confirms the pace of recovery. Cardio Diagnostics is also expanding partnerships with clinics, integrating epigenetic tests into primary care.

Tingkat bathi miturut bathi reged: Cardio Diagnostics Holdings, Inc. (CDIO) kanggo 28.04.2023 - 19.11.2026

Rincian metrik keuangan lan pasar Cardio Diagnostics (CDIO)

Pambiji fundamental:Cardio Diagnostics
Produk merek Cardio Diagnostics Holdings, Inc.

Analyzing the resilience of Cardio Diagnostics (CDIO) to market downturns requires an assessment of its core operational efficiency. Scaling B2B subscriptions for AI-driven genetic analysis platforms must translate into lower unit costs alongside revenue growth. The gross profit margin trend reflects the portion of funds remaining after deducting the cost of services, confirming the company's operational reliability and its ability to service its obligations.